The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH/ISH 2016 | Understanding the drivers behind disease with the 100,000 Genomes Project
Mark Caulfield, MD from Genomics England and Queen Mary University, London, UK gives an overview of the 100,000 Genomes Project, which is about sequencing the genomes of patients with rare inherited diseases, cancer and infections. The focus is on transforming the National Health Service (NHS) making the UK a world leader in the application of genomic medicine to healthcare. Prof Caulfield explains the challenges associated with analyzing tissue from tumors. He further discusses a programme that sequenced 150 patients with chronic lymphocytic leukemia (CLL) and plans for working on acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). The aim is to understand the drivers that lead to the disease, to response, relapse and outcomes.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland.
